Academic Journal
Προβολή σε EDS
Συνδεδεμένο Πλήρες Κείμενο

Neuroprotective potential of resveratrol in Parkinson, Huntington, amyotrophic lateral sclerosis, and multiple sclerosis: a comprehensive review.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Neuroprotective potential of resveratrol in Parkinson, Huntington, amyotrophic lateral sclerosis, and multiple sclerosis: a comprehensive review.
Συγγραφείς: Shahsavari K; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Yazarlu O; Department of General Surgery, Mashhad University of Medical Sciences, Mashhad, Iran. yazarlouom@mums.ac.ir., Ahmadnia H; Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran., Ardakani MT; Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran., Khanavi M; Department of Pharmacognosy, Faculty of Pharmacy, and Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran. khanavim@tums.ac.ir., Esfahani HM; Department of Pharmacognosy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran., Abdollahzadeh R; Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran., Sajedi A; MS and Neurology study group, Regenerative biomedicine Department, Royan institute for stem cell biology and technology and Arya group for treatment and research in MS and Neurological disease Tehran, Tehran, Iran., Kazemizadeh H; Thoracic Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Hasanpour M; Department of Pharmacognosy, Faculty of Pharmacy, and Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran. mhasanpour@farabi.tums.ac.ir.; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. mhasanpour@farabi.tums.ac.ir.
Πηγή: Molecular biology reports [Mol Biol Rep] 2026 Jul 04; Vol. 53 (1). Date of Electronic Publication: 2026 Jul 04.
Τύπος έκδοσης: Journal Article; Review
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Reidel Country of Publication: Netherlands NLM ID: 0403234 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-4978 (Electronic) Linking ISSN: 03014851 NLM ISO Abbreviation: Mol Biol Rep Subsets: MEDLINE
Imprint Name(s): Original Publication: Dordrecht, Boston, Reidel.
Ιατρικοί όροι (MeSH): Resveratrol*/pharmacology , Resveratrol*/therapeutic use , Neuroprotective Agents*/pharmacology , Neuroprotective Agents*/therapeutic use , Amyotrophic Lateral Sclerosis*/drug therapy , Amyotrophic Lateral Sclerosis*/metabolism , Multiple Sclerosis*/drug therapy , Multiple Sclerosis*/metabolism , Parkinson Disease*/drug therapy , Parkinson Disease*/metabolism , Huntington Disease*/drug therapy , Huntington Disease*/metabolism, Mitochondria/drug effects ; Mitochondria/metabolism ; Sirtuin 1/metabolism ; Humans ; Animals
Περίληψη: Resveratrol shows neuroprotective effects in preclinical studies across a number of neurodegenerative illnesses, including Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Huntington's disease (HD), and it enhances mitochondrial function through stimulation of the AMPK/SIRT1/PGC-1α pathway, thereby improving mitochondrial oxidative capacity and ATP generation. The natural polyphenol lowers α-synuclein accumulation and affects autophagy; both markers of PD. Combining nano‑resveratrol formulations with L‑DOPA has shown greater therapeutic efficacy in animal models (MPTP mouse), while co‑administration with EGCG has shown synergistic neuroprotection in vitro (SH‑SY5Y cells). These combination strategies offer potential advantages in neuroprotection and symptom alleviation while minimizing adverse drug effects. Resveratrol activates SIRT1 and AMPK signaling in preclinical models, enhancing mitochondrial biogenesis, lowering apoptosis, and restoring cellular resilience. The effectiveness of various models and dosages varies. The primary mechanism by which resveratrol promotes neuronal survival and remyelination in multiple sclerosis is through SIRT1 activation, which does not directly reduce inflammation. As innovative delivery systems, intranasal nanoparticles and exosomes produced from macrophages have shown improved CNS targeting accuracy. Resveratrol slows down neurodegeneration and improves the prognosis of HD by improving motor function and stimulating mitochondrial biogenesis in addition to activating neuroprotective ERK signaling. All of these results point to resveratrol's several pathways as a strong contender for neurodegenerative disease adjunctive treatment. The current evidence base is insufficient to support clinical use of resveratrol for any of the four diseases. Further rigorous preclinical studies (including TDP-43 models for ALS, SIRT1 knockout studies, and human-feasible dosing) and well-designed clinical trials with pharmacokinetic endpoints are required before any clinical recommendations can be made.
(© 2026. The Author(s), under exclusive licence to Springer Nature B.V.)
Competing Interests: Declarations. Conflict of interest: The authors declare there is no conflict of interest. Ethical Statement and Consent to Participate: This is a review article. Therefore, ethical approval is not required for the study. Human and Animal Rights: No animals/humans were used for studies that are the basis of this research.
References: Dugger BN, Dickson DW (2017) Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol (7):a028035.
Sweeney P et al (2017) Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener 6:6. (PMID: 28293421534878710.1186/s40035-017-0077-5)
Stephenson J et al (2018) Inflammation in CNS neurodegenerative diseases. Immunology 154(2):204–219. (PMID: 29513402598018510.1111/imm.12922)
Poewe W et al (2017) Parkinson disease. Nat Rev Dis Primers 3(1):1–21. (PMID: 10.1038/nrdp.2017.13)
Pandey KB, Rizvi SI (2009) Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2(5):270–278. (PMID: 20716914283591510.4161/oxim.2.5.9498)
Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5(6):493–506. (PMID: 1673222010.1038/nrd2060)
Barbosa LF et al (2010) Increased SOD1 association with chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-linked ALS. Biochim Biophys Acta 1802(5):462–71. (PMID: 2009728510.1016/j.bbadis.2010.01.011)
Arbo BD et al (2020) Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease. Front Aging Neurosci 12:103. (PMID: 32362821718034210.3389/fnagi.2020.00103)
Kung HC et al (2021) Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in Parkinson’s disease. Biomedicines. https://doi.org/10.3390/biomedicines9080918. (PMID: 10.3390/biomedicines9080918348298648615703)
Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373(9680):2055–66. (PMID: 1952478210.1016/S0140-6736(09)60492-X)
Jin F et al (2008) Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson’s disease in rats. Eur J Pharmacol 600(1–3):78–82. (PMID: 1894018910.1016/j.ejphar.2008.10.005)
Wu Y et al (2011) Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease. Neurosignals 19(3):163–174. (PMID: 21778691369981510.1159/000328516)
Albani D et al (2010) Neuroprotective properties of resveratrol in different neurodegenerative disorders. BioFactors 36(5):370–376. (PMID: 2084856010.1002/biof.118)
Khan MM et al (2010) Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson’s disease. Brain Res 1328:139–151. (PMID: 2016720610.1016/j.brainres.2010.02.031)
Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83–98. (PMID: 2116344610.1016/S1474-4422(10)70245-3)
Parker JA et al (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37(4):349–350. (PMID: 1579358910.1038/ng1534)
Ho DJ et al (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington’s disease. Exp Neurol 225(1):74–84. (PMID: 2056197910.1016/j.expneurol.2010.05.006)
Maher P et al (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington’s disease. Hum Mol Genet 20(2):261–270. (PMID: 2095244710.1093/hmg/ddq460)
Hardiman O, van den Berg LH, Kiernan MC (2011) Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 7(11):639–49. (PMID: 2198924710.1038/nrneurol.2011.153)
Mancuso R et al (2014) Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice. Neurotherapeutics 11(2):419–32. (PMID: 24414863399612410.1007/s13311-013-0253-y)
Markert CD et al (2010) A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J Med Food 13(5):1081–1085. (PMID: 2062625010.1089/jmf.2009.0243)
Wang J et al (2011) Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neurosci Lett 503(3):250–255. (PMID: 2189631610.1016/j.neulet.2011.08.047)
Yun YC et al (2019) Reduced sirtuin 1/adenosine monophosphate-activated protein kinase in amyotrophic lateral sclerosis patient-derived mesenchymal stem cells can be restored by resveratrol. J Tissue Eng Regen Med 13(1):110–115. (PMID: 30479062)
Thompson AJ et al (2018) Multiple sclerosis. Lancet 391(10130):1622–1636. (PMID: 2957650410.1016/S0140-6736(18)30481-1)
Singh NP et al (2007) Resveratrol (trans-3,5,4’-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72(6):1508–21. (PMID: 17872969479694910.1124/mol.107.038984)
Nimmagadda VK et al (2013) Overexpression of SIRT1 protein in neurons protects against experimental autoimmune encephalomyelitis through activation of multiple SIRT1 targets. J Immunol 190(9):4595–4607. (PMID: 23547115396327510.4049/jimmunol.1202584)
Fonseca-Kelly Z et al (2012) Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Front Neurol 3:84. (PMID: 22654783335957910.3389/fneur.2012.00084)
Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397(10291):2284–2303. (PMID: 3384846810.1016/S0140-6736(21)00218-X)
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912. (PMID: 2590408110.1016/S0140-6736(14)61393-3)
Shen DF et al (2023) Resveratrol Promotes Autophagy to Improve neuronal Injury in Parkinson’s Disease by Regulating SNHG1/miR-128-3p/SNCA Axis. Brain Sci, 13(8).
Wang ZH et al (2015) MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting alpha-synuclein expression in MPTP-induced Parkinson’s disease mouse. Biomed Pharmacother 74:252–256. (PMID: 2634999310.1016/j.biopha.2015.08.025)
Feng S et al (2025) Resveratrol Inhibits VDAC1-Mediated Mitochondrial Dysfunction to Mitigate Pathological Progression in Parkinson’s Disease Model. Mol Neurobiol 62(6):6636–6654. (PMID: 3881963510.1007/s12035-024-04234-0)
Xia D, Sui R, Zhang Z (2019) Administration of resveratrol improved Parkinson’s disease-like phenotype by suppressing apoptosis of neurons via modulating the MALAT1/miR-129/SNCA signaling pathway. J Cell Biochem 120(4):4942–4951. (PMID: 3026002510.1002/jcb.27769)
Ferretta A et al (2014) Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson’s disease. Biochim Biophys Acta 1842(7):902–915. (PMID: 2458259610.1016/j.bbadis.2014.02.010)
Palle S, Neerati P (2018) Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol 391(4):445–453. (PMID: 2941105510.1007/s00210-018-1474-8)
Gaballah HH et al (2016) Modulatory effects of resveratrol on endoplasmic reticulum stress-associated apoptosis and oxido-inflammatory markers in a rat model of rotenone-induced Parkinson’s disease. Chem Biol Interact 251:10–16. (PMID: 2701619110.1016/j.cbi.2016.03.023)
Lofrumento DD et al (2014) Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun 20(3):249–260. (PMID: 2376442810.1177/1753425913488429)
Liu Q et al (2019) Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice. Behav Brain Res 367:10–18. (PMID: 3092294010.1016/j.bbr.2019.03.043)
Li W et al (2020) Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson’s disease. Bioorg Chem 97:103707. (PMID: 3214617610.1016/j.bioorg.2020.103707)
Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease and monogenic parkinsonism. Neurobiol Dis 51:35–42. (PMID: 2306443610.1016/j.nbd.2012.10.011)
Youdim MB, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol 147(1):S287–S296. (PMID: 164021161760741)
Di L et al (2003) High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38(3):223–232. (PMID: 1266768910.1016/S0223-5234(03)00012-6)
Yang JT et al (2025) Resveratrol and ceftriaxone encapsulated in hybrid nanoparticles to prevent dopaminergic neurons from degeneration for Parkinson’s disease treatment. Biomater Adv 166:214065. (PMID: 3942617810.1016/j.bioadv.2024.214065)
Wang M et al (2018) Magnetic Resveratrol Liposomes as a New Theranostic Platform for Magnetic Resonance Imaging Guided Parkinson’s Disease Targeting Therapy. ACS Sustain Chem Eng 6(12):17124–17133. (PMID: 10.1021/acssuschemeng.8b04507)
Kuo YC, Wang IH, Rajesh R (2021) Use of leptin-conjugated phosphatidic acid liposomes with resveratrol and epigallocatechin gallate to protect dopaminergic neurons against apoptosis for Parkinson’s disease therapy. Acta Biomater 119:360–374. (PMID: 3318995310.1016/j.actbio.2020.11.015)
Bandiwadekar A et al (2025) Transdermal delivery of resveratrol loaded solid lipid nanoparticle as a microneedle patch: a novel approach for the treatment of Parkinson’s disease. Drug Deliv Transl Res 15(3):1043–1073. (PMID: 3894974610.1007/s13346-024-01656-0)
Kouli A, Torsney KM, Kuan W-L (2018) Parkinson’s disease: etiology, neuropathology, and pathogenesis. Exon Publications, pp 3–26.
Hardiman O et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3(1):1–19.
Neumann M et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130–133. (PMID: 1702365910.1126/science.1134108)
Ferraiuolo L et al (2011) Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 7(11):616–630. (PMID: 2205191410.1038/nrneurol.2011.152)
Edgar S et al (2021) Mutation analysis of SOD1, C9orf72, TARDBP and FUS genes in ethnically-diverse Malaysian patients with amyotrophic lateral sclerosis (ALS). Neurobiol Aging 108:200–206. (PMID: 3440455810.1016/j.neurobiolaging.2021.07.008)
Wong CO, Venkatachalam K (2019) Motor neurons from ALS patients with mutations in C9ORF72 and SOD1 exhibit distinct transcriptional landscapes. Hum Mol Genet 28(16):2799–2810. (PMID: 31107959668795010.1093/hmg/ddz104)
Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942–955. (PMID: 2129640510.1016/S0140-6736(10)61156-7)
Ruderman NB et al (2010) AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 298(4):E751–E760. (PMID: 20103737285321310.1152/ajpendo.00745.2009)
Kim D et al (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J 26(13):3169–3179. (PMID: 17581637191410610.1038/sj.emboj.7601758)
Yanez M et al (2011) CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res 1423:77–86. (PMID: 2198320510.1016/j.brainres.2011.09.025)
von Lewinski F, Keller BU (2005) Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci 28(9):494–500. (PMID: 10.1016/j.tins.2005.07.001)
Hamadeh MJ et al (2005) Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve 31(2):214–220. (PMID: 1562568810.1002/mus.20255)
Shindler KS et al (2007) SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 48(8):3602–3609. (PMID: 17652729196475310.1167/iovs.07-0131)
Shindler KS et al (2010) Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol 30(4):328–339. (PMID: 21107122331278410.1097/WNO.0b013e3181f7f833)
Ghaiad HR et al (2017) Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study. Mol Neurobiol 54(5):3219–3229. (PMID: 2706758910.1007/s12035-016-9891-5)
Gandy KAO et al (2019) Resveratrol (3, 5, 4’-Trihydroxy-trans-Stilbene) Attenuates a Mouse Model of Multiple Sclerosis by Altering the miR-124/Sphingosine Kinase 1 Axis in Encephalitogenic T Cells in the Brain. J Neuroimmune Pharmacol 14(3):462–477. (PMID: 30941623690092910.1007/s11481-019-09842-5)
Shamsher E et al (2024) Intranasal resveratrol nanoparticles enhance neuroprotection in a model of multiple sclerosis. Int J Mol Sci. https://doi.org/10.3390/ijms25074047. (PMID: 10.3390/ijms250740473861285611012060)
Dhuria SV, Hanson LR, Frey WH 2 (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(4):1654–1673.
Ross AG et al (2022) Selective upregulation of SIRT1 expression in retinal ganglion cells by AAV-mediated gene delivery increases neuronal cell survival and alleviates axon demyelination associated with optic neuritis. Biomolecules 12(6):830. (PMID: 35740955922109610.3390/biom12060830)
McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA 325(8):765–779. (PMID: 3362041110.1001/jama.2020.26858)
Zheng X et al (2023) Resveratrol-loaded macrophage exosomes alleviate multiple sclerosis through targeting microglia. J Control Release 353:675–684. (PMID: 3652168710.1016/j.jconrel.2022.12.026)
Keramatzadeh S et al (2025) Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial. Nutr Neurosci 28(7):854–862. (PMID: 3956503810.1080/1028415X.2024.2425649)
Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol 81(5–6):294–330. (PMID: 1737938510.1016/j.pneurobio.2007.01.003)
Walker FO (2007) Huntington’s disease. Lancet (London, England) 369(9557):218–228. (PMID: 1724028910.1016/S0140-6736(07)60111-1)
Jiang M et al (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington’s disease through activation of multiple Sirt1 targets. Nat Med 18(1):153–158. (PMID: 10.1038/nm.2558)
Jeong H et al (2012) Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 18(1):159–165. (PMID: 10.1038/nm.2559)
Naia L et al (2017) Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington’s disease models. Mol Neurobiol 54(7):5385–5399. (PMID: 2759014010.1007/s12035-016-0048-3)
Zhu L et al (2025) Interaction between resveratrol and SIRT1: role in neurodegenerative diseases. Naunyn Schmiedebergs Arch Pharmacol 398(1):89–101. (PMID: 3910579710.1007/s00210-024-03319-w)
Howitz KT et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954):191–196. (PMID: 1293961710.1038/nature01960)
Beher D et al (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74(6):619–624. (PMID: 1984307610.1111/j.1747-0285.2009.00901.x)
Pacholec M et al (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285(11):8340–8351. (PMID: 20061378283298410.1074/jbc.M109.088682)
Park SJ et al (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148(3):421–433. (PMID: 22304913343180110.1016/j.cell.2012.01.017)
Lagouge M et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127(6):1109–1122. (PMID: 1711257610.1016/j.cell.2006.11.013)
Cao Z et al (2023) 2-Hydroxy-4-benzyloxylimine resveratrol derivatives as potential multifunctional agents for the treatment of Parkinson’s disease. ChemMedChem 18(6):e202200629. (PMID: 3662294710.1002/cmdc.202200629)
Tao J et al (2023) The protective role of microbiota in the prevention of MPTP/P-induced Parkinson’s disease by resveratrol. Food Funct 14(10):4647–4661. (PMID: 3710232010.1039/D2FO03379H)
Pangeni R et al (2014) Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress. Nanotechnology 25(48):485102. (PMID: 2539220310.1088/0957-4484/25/48/485102)
Abolaji AO et al (2025) Experimental and computational insights into the therapeutic mechanisms of resveratrol in a Drosophila alpha-synuclein model of Parkinson’s disease. Sci Rep 15(1):17769. (PMID: 404046731209899710.1038/s41598-025-00698-9)
Contributed Indexing: Keywords: Amyotrophic Lateral Sclerosis; Huntington’s Disease; Multiple Sclerosis; Neuroprotective; Parkinson’s Disease; Resveratrol
Substance Nomenclature: Q369O8926L (Resveratrol)
0 (Neuroprotective Agents)
EC 3.5.1.- (Sirtuin 1)
Entry Date(s): Date Created: 20260704 Date Completed: 20260704 Latest Revision: 20260704
Update Code: 20260705
DOI: 10.1007/s11033-026-12300-0
PMID: 42400730
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1573-4978
DOI:10.1007/s11033-026-12300-0